Results From Galderma’s Phase IIIb Trials Demonstrate Rapid and Long-Lasting Effect of Relabotulinum
ZUG, Switzerland - Thursday, 30. November 2023 Both trials met their primary endpoints, demonstrating treatment with RelabotulinumtoxinA...